Tokyo Century Corporation and All Nippon Airways Trading Company to Acquire Significant Stake in GA Telesis
GA Telesis, LLC (“GA Telesis” or “the Company”) announced today that its current shareholder Tokyo Century Corporation (“Tokyo Century”) along with All Nippon Airways Trading Company (“ANATC”)1, have collectively entered into a definitive agreement to acquire all shares held by Global Principal Finance Company LLC (“GPFC”)2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180930005012/en/
Tokyo Century Corporation and All Nippon Airways Trading Company to Acquire Significant Stake in GA Telesis. (Photo: Business Wire)
Tokyo Century’s ownership after the closing of the transaction will increase to 49.2% and ANATC will acquire a 10% interest in the Company. Tokyo Century and ANATC expect the transaction to close in October 2018.
Separately, GA Telesis, Tokyo Century and ANATC have reached an in-principle agreement to form a commercial engine leasing joint venture focusing on current technology jet engines. The equity will be provided by each party and the joint venture will be managed by GA Telesis.
The additional investment by Tokyo Century will bolster and further diversify Tokyo Century’s existing aviation investment platform, which also includes a 20% holding in Aviation Capital Group, the world’s premier aircraft leasing company, as well as a 16.7% position in Jetstar Japan.
"Our initial investment in GA Telesis from 2012 has performed well and proven our initial investment thesis," said Koichi Nakajima, Deputy President of Tokyo Century Corporation. "We have made a commitment to our customers and the industry to provide the best services in aviation. This further investment in the Company solidifies our strategy and promise.”
Established in 1970, ANATC has evolved from a service provider of aviation serviceable parts to a multinational service and solution provider that centers its business not only around aviation, but also in various fields such as food and beverages, electronics, and daily living essentials. Building on a strong customer base in Asia and other regions, ANATC strives to provide customer-centric and value-added solutions and services to its customers.
"This investment in GA Telesis is the next step in our growth strategy, with a clear opportunity to profitably grow our business and better serve our customers," said Hideto Osada, Senior Executive President of ANATC.
With approximately 600 employees worldwide, GA Telesis is headquartered in Ft. Lauderdale, Florida with financial services, sales, distribution operations and MRO services operations in more than 19 countries. As the leading independent provider of integrated solutions through the combination of financial services, used serviceable material supply-chain, major related MRO operations and other ancillary aftermarket services, GA Telesis continues to lead the industry by expanding the GA Telesis Ecosystem™ to include more product and service offerings to its customers.
“I am thrilled with Tokyo Century’s confidence in GA Telesis and decision to increase its stake in GA Telesis,” said Abdol Moabery, President & CEO of GA Telesis. “We have had a 15-year relationship with ANATC and their investment is not only a testament to the success of that relationship but also the innovative manner in which they view the future of the aviation marketplace. With these two great shareholders, I am confident that we will continue to deliver our year-on-year double-digit growth,” he added.
About Tokyo Century Corporation
Tokyo Century Corporation is a highly specialized and unique financial services company that pioneers new business fields combining finance, services and business expertise, working alongside customers in pursuit of their growth and goals. Through its four core businesses (Equipment Leasing, Specialty Financing, Domestic Automobile Financing, and International Business) Tokyo Century seeks to provide solutions that help increase the corporate value of customers.
About All Nippon Airways Trading Company
ANATC is a global solution and service provider, focusing in five business areas: retail, digital marketing, food, aerospace and electronics, and lifestyle businesses. ANATC headquartered in Tokyo, Japan, has business units in France and Singapore, and 11 group companies, with a multinational workforce of approximately 2,300 people.
About GA Telesis
GA Telesis is a global leader providing integrated solutions to the aviation and aerospace industries. Built on the premise of “Customer Success” being the goal, GA Telesis serves over 3,000 customers including airlines, OEMs, MROs and suppliers worldwide with 31 leasing, sales, distribution and MRO operations in 19 countries. At GA Telesis the company’s core business is integrated aviation solutions and their mission is customer success.
1 ANATC is a wholly owned subsidiary of ANA Holdings
2 Global Principal Finance Company LLC is a wholly owned subsidiary of Bank of America Corporation
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180930005012/en/
Contact information
GA Telesis, LLC
Cathy Moabery, 954-676-3111 Ext. 2238
cmoabery@gatelesis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom